SSG
BMY.RT

Summit Securities Group’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Summit Securities Group’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-72,400
Closed -$50K – 837
2020
Q4 		$50K Sell
72,400
-57,000
-44% -$121K ﹤0.01% 542
2020
Q3 		$291K Buy
129,400
+18,000
+16% +$51.4K 0.03% 287
2020
Q2 		$399K Sell
111,400
-52,100
-32% -$188K 0.05% 266
2020
Q1 		$621K Buy
163,500
+20,300
+14% +$66.9K 0.11% 148
2019
Q4 		$431K Buy
+143,200
New +$372K 0.03% 298

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Summit Securities Group's BMY.RT Position: Q1 2021 in Review

Summit Securities Group sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 72,400 shares — an estimated $50K sold.

Summit Securities Group first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $621K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Summit Securities Group reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Summit Securities Group sold 72,400 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $50K.
  • Summit Securities Group first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Summit Securities Group's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $621K in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Summit Securities Group's 13F filing for Q1 2021, filed 14 Apr 2021.